[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
August 2009

Cytomegalovirus Infection in a Patient Treated With Efalizumab for Psoriasis

Arch Dermatol. 2009;145(8):961-962. doi:10.1001/archdermatol.2009.154

Cytomegalovirus (CMV) is characterized by lifelong latent infection following primary infection. Prevalence of viral carriage in adult populations is high. Infections with CMV in immunocompetent persons are usually asymptomatic, but in the immunocompromised patient, primary infection or reactivation of latent infection may be severe.

Efalizumab is a humanized monoclonal antibody that blocks lymphocyte activation and migration. We describe herein a case of CMV infection occurring in a patient with psoriasis who was undergoing efalizumab therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×